Podcasts about OTC

XRP: Final Battle | Flare FIXES DeFi | Somalia Fraud ERUPTS Nationwide

Building a brand, helping create a category, reaching a previously underserved consumer—none of these is an easy task. Yet contemporary menopause care brands are taking on all of these challenges. This week on the CosmoFactory podcast, we consider the risks and rewards of creating an OTC brand for the generation-spanning demographic of menopause consumers. Our guest is Sally Mueller, Co-Founder and CEO of Womaness. The US-based wellness brand was founded in 2020 with an ambition to ‘modernize aging'. The Womaness portfolio spans skincare, body care, sexual wellness products, and supplements—products consumers find at both general merchandise and specialty retailers, including  Ulta Beauty, Target, QVC, Amazon, and the Womaness ecommerce site.   If you enjoy this episode, SHARE it with a friend, FOLLOW the CosmoFactory podcast & please LEAVE A REVIEW today. With your help, even more cosmetic industry professionals can discover the inspiring interviews we share on CosmoFactory! ABOUT CosmoFactoryBeauty industry stakeholders listen to the CosmoFactory podcast for inspiration and for up-to-date information on concepts, tactics, and solutions that move business forward. CosmoFactory – Ideas to Innovation is a weekly interview series for cosmetics and personal care suppliers, finished product brand leaders, retailers, buyers, importers, and distributors. Each Tuesday, CosmoFactory guests share experiences, insights, and exclusive behind-the-scenes details—which makes this not only a must-listen B2B podcast but an ongoing case study of our dynamic industry. Guests are actively working in hands-on innovation roles along the beauty industry supply chain; they specialize in raw materials, ingredients, manufacturing, packaging, and more. They are designers, R&D or R&I pros, technical experts, product developers, key decision makers, visionary executives. HOST Deanna UtroskeCosmetics and personal care industry observer Deanna Utroske hosts the CosmoFactory podcast. She brings an editorial perspective and over a decade of industry expertise to every interview. Deanna is also Editor of the Beauty Insights newsletter and a supply-side consultant. She previously wrote the Global Perspectives column for EuroCosmetics magazine, is a former Editor of CosmeticsDesign, and is known globally for her ability to identify emerging trends, novel technologies, and true innovation in beauty. A PRODUCTION OF Cosmoprof Worldwide BolognaCosmoFactory is the first podcast from Cosmoprof Worldwide Bologna, taking its place among the best B2B podcasts serving the global beauty industry.   Cosmoprof Worldwide Bologna is the most important beauty trade show in the world. Dedicated to all sectors of the industry, Cosmoprof Worldwide Bologna welcomes over 250,000 visitors from 150 countries and regions and nearly 3,000 exhibitors to Bologna, Italy, each year. It's where our diverse and international industry comes together to build business relationships and to discover the best brands and newest innovations across consumer beauty, professional beauty, and the entire supply chain. The trade show includes a robust program of exclusive educational content, featuring  executives and key opinion leaders from every sector of the cosmetics, fragrance, and personal care industry. Cosmoprof Worldwide Bologna is the most important event of the Cosmoprof international network, with exhibitions in Asia (Hong Kong), the US (Las Vegas and Miami), India (Mumbai) and Thailand (Bangkok). Thanks to its global exhibitions Cosmoprof connects a community of more than 500,000 beauty stakeholders and 10,000 companies from 190 countries and regions. Learn more today at Cosmoprof.com         

The Week 13 NFL slate was a gross one after all of the premium games of the week were taken by Thanksgiving and Black Friday. Somehow, AD Mitchell was the guy you needed. Big weeks from Brock Bowers and Trey McBride were also useful across the DFS and best ball landscape.

Ripple vs Solana: Insider EXPOSES the Difference | XRP Narrative Off The Rails Tonight we break down the latest wave of crypto and geopolitical chaos: CRYPTO: • Ripple's killer analogy comparing early texting revenue to today's crypto rails • A former Solana employee now at Ripple explaining the real differences between the ecosystems • Why people online are connecting completely FAKE “chosen in 1992” XRP conspiracy dots • What all of this means for adoption, utility, and where XRP fits in the changing crypto landscape GEOPOLITICS: • Tim Walz goes viral for all the wrong reasons • “Experts” suffer a brutal narrative collapse over Black Friday weekend • Why mainstream coordination is breaking down in real time • How these political fractures connect back to crypto, decentralization, and the fight for transparency This episode gets into the tech, the signal, and the political reality — the stuff the media won't touch. Join Chip & Jeff on On The Chain — the best damn crypto + geopolitical blend on YouTube. Subscribe & comment — let's get into it.

XRP Adoption EXPLODES worldwide — from the UK to Abu Dhabi to Korea — and the global realignment in crypto is moving FAST. TODAY WE COVER:

Coffee with Samso | Episode 213 | London - UK, Perth - Western Australia. Guest: Oliver Friesen – CEo & Executive Director, Guardian Metals Resources Plc (LON: GMET - OTCAX: GMTLF)     Introduction In this episode of Coffee with Samso, I speak with Oliver Frieson, the CEO and Executive Director of Guardian Metals Resources PLC, about one of the most compelling but under-discussed metals in the global supply chain — tungsten. With prices at all-time highs, export bans in place from China, and increasing geopolitical interest, tungsten is now firmly at the centre of the strategic resources conversation. Guardian Metals, listed on the LSE and OTC, is a rare story that began long before the market caught on — positioning itself as a serious player in the US critical minerals space. This Coffee with Samso explores the macro forces driving the tungsten narrative, the market imbalance between China and the West, and Guardian's role as a key part of the solution. This is a conversation that is highlighted only because the underlying business is not in the headlines.   The Business of the Company: Focus – US Tungsten Projects Guardian Metals Resources has two strategic assets: Pilot Mountain, Nevada – One of the largest historical tungsten projects in the US, previously mined during World War II and advanced with a robust ongoing PFS process. Tempuite, Nevada – Formerly the largest producing tungsten mine in the US during the 1980s, now being revitalised with a current drill program and site refurbishment underway. With processing infrastructure already existing in Nevada and strong institutional support, Guardian is aiming to bring both mines into production before the end of the current US administration.   Global Tungsten Market – Highlights from the Conversation China Has Weaponised Supply Since Feb 2025, Chinese exports of tungsten have virtually ceased. China continues to import and stockpile tungsten despite being the largest producer — creating a supply/demand distortion. Domestic Chinese prices have exceeded international prices — a counterintuitive signal suggesting internal demand pressures. Western Supply Gap is Real Global tungsten demand: ~100,000–120,000 tonnes/year. Western world mine production: ~10,000 tonnes/year. Net gap outside of China/Russia/North Korea: ~40,000–50,000 tonnes/year. New Equilibrium Price Forming Historically, tungsten projects needed USD $500+/MTU to be viable. Current prices: USD $620–630/MTU with upside momentum. Guardian's projects were viable even at pre-2020 pricing norms — giving them a competitive advantage in a rising-price environment. Leadership Commentary – Oliver Frieson's Perspective Oliver brings a unique lens — a geologist by trade, Canadian by background, and now building a US-focused tungsten strategy from London. He shared: Guardian's five-year journey into tungsten (well before the current hype). Why he believes domestic mine supply is now a national imperative. How Guardian has already received US Department of Defense funding for its Pilot Mountain project. The critical difference between companies "mining the market" and those genuinely positioned to deliver a sellable product. "We've spent five years building this position. Now everyone is paying attention, but we were early — and we have the right assets in the right place." About the Projects Pilot Mountain: Located in mining-friendly Nevada. Historical producer during WWII. Ongoing PFS+ study with engineering, metallurgy, geotech, and mine design in progress. Pilot North staked as potential hub-spoke satellite to main project. Tempuite: Previously produced 0.45% WO3 grades – high for tungsten. All infrastructure still on site: mill foundation, substation, office. Currently undergoing resource upgrade drilling. Goal is to bypass scoping and move into DFS-level work. How Samso Understands the Investment Memo for the Company Guardian Metals is a real-time case study in: Early contrarian entry into a critical metal market Operating in one of the only jurisdictions with full processing infrastructure Holding assets with historic production, existing infrastructure, and proven metallurgy Aligning with national strategy: awarded US DoD funding, exploring within strategic minerals legislation In a field crowded with hype, Guardian is already executing. Samso Concluding Comments Guardian's story is a reminder that real value often comes from being early. From my early experience with the Tungsten story, the current macro picture for tungsten is unprecedented — geopolitical shifts, price surges, and the weaponisation of exports all highlight how exposed the West has become. Guardian's Nevada projects are ticking the right boxes — grade, infrastructure, timing, jurisdiction. There's real substance here, and it's worth keeping a close eye on as both projects move forward. In the words of Samso, get your favourite beverage and sit and listen to another great insight from Coffee with Samso.

En este quinto episodio de Bolsa de Valores, el Podcast, te acompaño en un recorrido profundo, pero claro, por algunos de los temas más técnicos y estratégicos del mundo financiero: curvas de valuación, la TIIE de Fondeo, derivados OTC vs. estandarizados y notas estructuradas.Soy Francisco González, Director General de Valmer, y en esta ocasión converso con Pedro Arroyo Espinoza, Director de Operación de Derivados en Monex, para desmitificar estos conceptos que, aunque complejos, son clave para la toma de decisiones financieras en mercados sofisticados.Hablamos de:¿Qué es la curva de TIIE de Fondeo y por qué es tan relevante hoy?Las diferencias entre derivados OTC y estandarizados (y cuándo usarlos)Cómo se construye una curva de tasas y su impacto en la valuación de instrumentos¿Qué son las notas estructuradas, por qué son atractivas y para quiénes?Este episodio es ideal si quieres entender cómo la técnica detrás de las curvas y derivados impulsa la innovación financiera, la gestión de riesgos y el diseño de portafolios más eficientes. No importa si eres nuevo en estos temas o si ya trabajas en la industria: aquí encontrarás explicaciones claras, ejemplos útiles y contexto actual.

XRP ETF Heats Up | NY AG Bombshell: BitLicense ILLEGAL? Tonight on On The Chain, Jeff and Chip break down huge developments across crypto and geopolitics:

Coughs, Flu and School Germs, oh my!If cold-and-flu season causes tremors in your heart but you hate the idea of using over-the-counter drugs on your kids just to get through the night, I have great news: The bees got your back.Carly from Beekeeper's Naturals joins us today to share about the power of nature – she will feed your science geek brain and share SO many practical ideas and uses for bee products (bet you've never even heard of some of them!):What beats coughs as effectively as OTC cough meds but with no side effects?Find out about a natural anti-bacterial, anti-viral, anti-fungal product that you can ingest or use on the skin for coughs, rashes, scrapes, immunity boosting, allergies, and “that ominous tickle.” Amazing stuff!What gives queen bees the vitality to have 1500 babies a day and live 20x longer than other bees? Want some? Humans have been using it for centuries!Two different ways to calm anxiety and get better sleep, something we know everyone needs!Find incredible focus with an age-old nootropic that may help heal concussions, build new brain cells, prevent signs of aging brains and more…this stuff is so cool!!Resources We Mention About Health Benefits of HoneyShop Beekeepers Naturals (use code KITCHEN20 for 20% off!)Pre-order Carly's picture book, Little Bee and the Bloom (releasing August 2026) on Amazon or Bookshop.orgHow to Bake with HoneyMy interview with Carly about bee population declineMore ways to improve sleepHealth benefits of honeyMore natural ways to combat coughs and coldsFind Beekeeper's Naturals on Instagram or FacebookShop Wholestix and eat your organ meats here! Kitchen Stewardship Kids Cook Real Food follow Katie on Instagram or Facebook Subscribe to the newsletter to get weekly updates YouTube shorts channel for HPH Find the Healthy Parenting Handbook at kidscookrealfood.com/podcast Affiliate links used here. Thanks for supporting the Healthy Parenting Handbook!

FinPod: Interest Rate Swaps Masterclass: Modeling SOFR & The End of LIBORThe Interest Rate Swap (IRS) market, the biggest derivative contract in the world, has undergone a massive overhaul. LIBOR is gone, and the way plain vanilla swaps are traded has changed dramatically.Join us to discuss the new Interest Rate Swap course, which fully reflects these 2025 market realities and provides the up-to-date, essential knowledge you need.This episode covers:The LIBOR Revolution: Why the global benchmark was discontinued and how the industry pivoted to new Alternative Reference Rates (ARRs) like SOFR, Sonya, and ESTR.OTC vs. Exchange-Traded: The fundamental shift in how swaps are traded, moving from private Over-the-Counter (OTC) negotiation to regulated Swap Execution Facilities (SEFs), introducing daily margin calls and mark-to-market.Hands-On Modeling: You will learn to bootstrap forward rate curves to determine implied forward and zero rates, and model the valuation of a swap's fixed and floating legs.Real-World Application: We walk through modeling a real-life SOFR swap using actual market data examples (Refinitiv screens), giving you practical, up-to-date skills.Master the most critical product in the derivatives market and ensure your knowledge is current with the post-LIBOR financial landscape.

It's been another jet-setting couple of weeks for the Harena team. Company executives and management have recently spent extensive time with the new government of Madagascar, building relationships ahead of the granting of the the permit for the Ampasindava rare earths project on the north coast. Across the Atlantic there have also been meetings with high echelons in the US government following on from the company's listing on the OTC. Executive chairman Ivan Murphy joins Vox to tell us what's been going on, to lay out the upcoming newsflow, and to remind us just how big the opportunity is at Ampasindava

A growing number of people are exploring hearing help earlier, and LXE Hearing believes there is a place for devices that bridge the gap between everyday earbuds and traditional hearing aids. In a detailed discussion, LXE Chief Commercial Officer Brian Maguire explains how the newly formed company—created from the merger of Lexie, hearX, and Eargo—is blending strong hardware engineering with deep software expertise to develop more accessible hearing solutions. Maguire describes LXE's portfolio, from diagnostics and screening tools to OTC devices, and emphasizes the group's shared mission: helping people better understand their hearing and giving them approachable, affordable entry points into amplification.The conversation centers on the Lexie H1 hearing buds, LXE's new earbud-style hearing device designed for situational use. Maguire explains that while traditional CIC and RIC hearing aids remain their core offerings, a growing group of consumers wants an option that boosts hearing only when needed—especially in noisy environments—without the commitment of full-time wear. He highlights the H1's dual purpose: it functions as a high-quality, everyday wireless earbud with streaming and ANC, but also incorporates hearing amplification with preset programs, adjustable gain through the app, reduced occlusion, and features like directivity and noise reduction for speech-in-noise challenges.Maguire stresses that the H1 isn't meant to replace all-day devices but to complement them, helping newcomers try amplification sooner and giving existing hearing aid users a tool for specific listening situations. With flexible support, a 45-day risk-free trial, and a $299 price point, he says LXE hopes the H1 will encourage more people to take their first steps toward hearing improvement—at a time when awareness and comfort with ear-worn tech are rapidly increasing.Lexie H1 Hearing Buds press release: https://hearinghealthmatters.org/hearing-technologies/2025/lexie-hearing-h1-hearing-buds/Be sure to subscribe to our channel for the latest episodes each week and follow This Week in Hearing on LinkedIn, Instagram and X.- https://x.com/WeekinHearing- https://www.instagram.com/thisweekinhearing/- https://www.linkedin.com/company/this-week-in-hearingVisit us at: https://hearinghealthmatters.org/thisweek/

XRP: FLARE Drops BIG Upgrades — NEW MONEY Coming In | Protecting The Republic From Sedition Today we cover two major fronts: massive crypto developments and growing threats to the American Republic.

In this powerful and informative episode of The Neil Haley Show, actress, author, and mom Tori Spelling joins board-certified dermatologist Dr. Adam Friedman to discuss a deeply personal topic affecting millions: eczema.Together, they bring awareness to the Free to Be Me Campaign, encouraging individuals with dry, itchy, inflamed skin to openly discuss their symptoms and work with a healthcare provider to find effective treatment options.Tori shares her emotional journey with eczema — from her first adult flare-up during an extremely stressful period, to raising her daughter Stella, who developed the condition as a young child. After years of trying steroid creams, home remedies, and over-the-counter products that didn't bring relief, Tori and Stella finally found success with Zoryve, a once-daily, steroid-free treatment.Dr. Friedman breaks down the science behind eczema, common triggers, how it's diagnosed, and why steroid-free options are so meaningful for long-term relief.This heartfelt and educational episode brings both empathy and expertise — reassuring families that they're not alone and that treatment options exist.• Developed eczema as an adult during her first divorce• Stress triggered severe flare-ups requiring wardrobe changes on set• Her daughter Stella developed eczema in early childhood• Relief finally came with Zoryve, a once-a-day, steroid-free treatment• Emotional impact of seeing Stella bullied at school• Misconceptions about the condition (“Is it contagious?”)• Home remedies: oatmeal baths, OTC creams, steroid creams — none long-term• How eczema affects confidence, style choices, and social comfort• Eczema is common, genetic, and often linked with asthma/allergies• No blood test — diagnosis is clinical• Symptoms include dryness, redness, itching, bumps, scaling• Triggers include stress, climate, allergens, and irritants• Steroid phobia is real — patients often hesitate to use steroid creams• Why Zoryve matters for long-term safetyZoryve Cream 0.15% (roflumilast)• Once daily• Steroid-free• Lightweight and non-greasy• Side effects may include headache, nausea, diarrhea, vomiting, or application-site pain• A meaningful option for long-term management• Speak up — don't suffer in silence• You are NOT alone• Confidence grows when symptoms are controlled• Open conversations lead to real solutions• Encourages families to visit Zoryve.com for information• Hosting her personal podcast misSPELLING• Co-hosting 9021OMG with former co-star Jenny Garth• Continuing her entrepreneurial projects• Raising five children as a full-time hands-on mom“Mine started because of stress — but I had no idea what was happening.” — Tori Spelling“I tried everything for Stella. Nothing worked long-term, and I didn't want her on steroids forever.” — Tori Spelling“I just want people to talk about it. Eczema is common — there should be no shame.” — Tori Spelling“Diagnosis is clinical. Eczema can look like so many conditions, so talk to a dermatologist.” — Dr. Adam Friedman“You only get better if you use the medication — and steroid fear often gets in the way.” — Dr. Adam Friedman• Actress, producer, author• Known for Beverly Hills, 90210 and her reality series• Podcast host: misSPELLING• Co-host of 9021OMG• Mom of five• Advocate for eczema awareness and the Free To Be Me campaign• Board-certified dermatologist• Professor and Chair, Department of Dermatology at George Washington University• Nationally recognized eczema expert• Advocate for accessible, effective, steroid-free treatmentsVisit Zoryve.com to explore treatment information and resources.Always speak with a healthcare provider to determine what's right for you.

Learn how to choose the right hearing aids with expert guidance on OTC vs. prescription options, hearing tests, and proper fit. Clear, practical insights to help you make confident decisions.   To see the video edition of this episode with closed captioning, please go to

Ben Nadareski is the CEO and Co-Founder of Solstice Labs, where he's redefining how yield is generated in DeFi. Backed by Deus X Capital, Solstice Labs pioneers permissionless, institutional-grade strategies on Solana, making sophisticated trading approaches and sustainable yields accessible to everyone.Previously, Ben led the first crypto-derivative trades with global banks as Vice President of Global Trading at Galaxy Digital. He advanced strategic investments in digital assets as Director of M&A at SIX Digital Exchange, helped expand blockchain adoption across Asia with R3 by introducing decentralized tech to central banks and financial institutions, and developed onchain OTC data networks while leading global business development at DrumG, a Consensys-backed startup.Ben has served as a guest lecturer at the Wharton School of Business on topics including crypto, DeFi and capital markets. Prior to his 2013 leap into web3, Ben worked on the Interest Rate and FX Derivates trading desk at Société Générale. He comes from a scientific background as a published nuclear physics researcher with a degree in Physics,  and still today, applies that same scientific rigor to his work in crypto.In this conversation, we discuss:- The rise of Solana and its ecosystem - Solana bull case  - Building the Yield Engine for Solana's Next Chapter  - The Role of DeFi, Stablecoins, and yield-vaults  on Solana (USX) - The Risk Engine is evolving into a Yield Engine - Solana inflation - One-click yield system - Having a Sharp rate of 8 Solstice LabsX: @solsticefiWebsite: solstice.financeLinkedIn: Solstice Labs AGBen NadareskiX: @ben_solsticeLinkedIn: Ben Nadareski---------------------------------------------------------------------------------This episode is brought to you by PrimeXBT.PrimeXBT offers a robust trading system for both beginners and professional traders that demand highly reliable market data and performance. Traders of all experience levels can easily design and customize layouts and widgets to best fit their trading style. PrimeXBT is always offering innovative products and professional trading conditions to all customers.  PrimeXBT is running an exclusive promotion for listeners of the podcast. After making your first deposit, 50% of that first deposit will be credited to your account as a bonus that can be used as additional collateral to open positions. Code: CRYPTONEWS50 This promotion is available for a month after activation. Click the link below: PrimeXBT x CRYPTONEWS50FollowApple PodcastsSpotifyAmazon MusicRSS FeedSee AllFollowApple PodcastsSpotifyAmazon Music

BIGGEST XRP NEWS Since 2012? | Staking | Flare Deflationary Ripple engineers are openly discussing native XRP staking, governance upgrades, and on-chain DeFi capabilities — something the XRPL community has waited years to hear. If implemented, this could be the biggest shift since 2012, unlocking new utility, yield mechanics, and deeper network participation. At the same time, Flare Network just dropped a massive update: Hugo Philion revealed they're exploring ways to make FLR non-inflationary — or even deflationary. This could completely transform the tokenomics model and re-rate the entire ecosystem. Tonight we break down: • Ripple's staking discussion • Akinyele & Schwartz on governance + programmability • What staking would mean for XRP utility • How much supply could be locked up • Flare's path toward deflation • The broader impact on crypto markets This is one you don't want to miss.

In this episode, we cover institutional crypto adoption, stablecoins' interplay with treasuries and 24/7 repo financing on Canton, the risks associated with wrapped assets and stablecoin fragmentation, and 2026 expectations for broader, client-driven OTC and onchain activity.   -- Quadrillions brings together the voices defining the next era of finance. From institutional rails to stablecoins and privacy, the series dives into how traditional markets, crypto innovation, and regulatory frameworks are converging to bring the full force of capital markets onchain. Join hosts Jason Yanowitz, Yuval Rooz, and Eric Saraniecki for deep dives with special guests Shaul Kfir, Don Wilson, Mike Belshe, Justin Peterson, Acting Chair Caroline Pham, Eli Ben-Sasson, and more. Produced by Blockworks and Canton Network. For more information, check out https://quadrillionspod.com/ -- Follow Canton: https://x.com/CantonNetwork Follow Tradeweb: https://x.com/Tradeweb Follow Mike: https://x.com/mikebelshe Follow Eric: https://x.com/wesarn_real Follow Empire: https://twitter.com/theempirepod -- Timestamps: (0:00) Introduction (1:38) Tradeweb's Origin Story (3:58) The State of Institutional Crypto Adoption (8:23) Where is the Most Growth Right Now? (10:26) Consolidating Stablecoins (15:23) Tradeweb's Crypto Strategy (18:32) What Does Crypto Solve Today? (23:37) The Next 100x Growth Opportunity (27:56) Bringing RWAs Onchain (31:25) The Role of Custodians (35:03) Canton's Go-to-market Strategy (38:31) Tokenized Equities (44:02) The Need For Privacy (49:23) Crypto Adoption Going Forward -- Disclaimer: “Quadrillions” is a mini-series produced by Blockworks, and is sponsored by Canton Network. Nothing on this show is a recommendation to buy or sell securities or tokens. It's for informational purposes only, and the views expressed by anyone on the show are solely their opinions, not financial advice or necessarily the views of Blockworks. Our hosts, guests, and the Blockworks team may hold positions in companies, funds, or projects discussed, including those related to Canton Network.

The UK's consumer healthcare industry association, PAGB is publishing a series of blog posts for Self-Care Week – an annual awareness campaign in the UK organized by the Self Care Forum, held this year from 17-23 November. In this second part of a special episode of HBW Insight's Over the Counter podcast, we catch up with the association's CEO Michelle Riddalls, to talk about what the association is doing to promote digital health. As part of the UK government's plans for reforming the country's National Health Service, PAGB is asking for the widely used UK NHS app to not only advise people on how to self-care but also to take users to OTC brand websites that can help them to self-manage their conditions appropriately. We also discuss the advantage of having digital apps and self-care information generally linked to trusted umbrella brands. Timestamps 2:00 – PAGB's digital health strategy 6:00 – The NHS app and self-care brands 12:00 – Self-care apps 15:30 – The importance of brands Guest Bio Michelle Riddalls OBE is chief executive officer of PAGB, the consumer healthcare association, which represents the manufacturers of branded OTC medicines, self-care medical devices and food supplements in the UK. Prior to joining PAGB, Riddalls was director of regulatory affairs for the Northern European Cluster at Pfizer Consumer Healthcare, where she was integral in the highly successful POM to GSL reclassification of Nexium Control and the Viagra Connect POM to P switch. Michelle has been recognized across a number of industry awards, including the Women in Trade Powerlist in 2024, and was awarded an OBE for outstanding services to consumer health in the King's 2025 New Year Honours.

The UK's consumer healthcare industry association, PAGB is publishing a series of blog posts for Self-Care Week – an annual awareness campaign in the UK organized by the Self Care Forum, held this year from 17-23 November. In this special episode of HBW Insight's Over the Counter podcast, we catch up with the association's CEO Michelle Riddalls, to talk about what the association is doing to promote Rx-to-OTC switch in the UK. According to Riddalls, two-thirds of PAGB members see reclassification as a key pillar of growth in the next 10-15 years. The UK government has also announced it wants to see switch applications for 16 medical conditions and categories, including sleep, pain, allergy and women's intimate health. Through initiatives like the Reclassification Alliance, PAGB is working hard to unlock this significant growth opportunity for the UK consumer health industry, Riddalls explains. Timestamps 3:00 – Introductions 4:00 – PAGB and Self-Care Week 5:30 – How PAGB is helping to enable Rx-to-OTC switch 8:00 – The benefits of switching for the consumer health industry 11:00 – Riddalls' switch experience 15:00 – UK government's switch agenda 18:00 – Switch barriers 22:00 – Thinking outside the box Guest Bio Michelle Riddalls OBE is chief executive officer of PAGB, the consumer healthcare association, which represents the manufacturers of branded OTC medicines, self-care medical devices and food supplements in the UK. Prior to joining PAGB, Riddalls was director of regulatory affairs for the Northern European Cluster at Pfizer Consumer Healthcare, where she was integral in the highly successful POM to GSL reclassification of Nexium Control and the Viagra Connect POM to P switch. Michelle has been recognized across a number of industry awards, including the Women in Trade Powerlist in 2024, and was awarded an OBE for outstanding services to consumer health in the King's 2025 New Year Honours.

The best biotech and pharmaceutical innovations mean nothing if they can't be protected—and protected fast. Our next guest, Josh Goldberg, is solving this challenge as co-managing partner at Nath, Goldberg & Meyer, the #1 ranked patent law firm for biotech and pharmaceutical technologies. With nearly three decades of IP law experience and a unique background as a lab researcher, Josh brings an insider's understanding of how innovation actually happens. He's helped industry leaders like Amgen, Takeda, and GlaxoSmithKline turn breakthrough treatments into patent-protected portfolios—often in under a year instead of the typical four-year timeline. Driven by a passion for focus and strategic IP timing, Josh shares his pioneering approach to biotech and pharmaceutical patent prosecution. Join us to discover how smart IP strategy drives licensing power, regulatory success, and company valuation. Let's go!Episode Highlights:Focus drives success – Companies fail by trying to do everything at once; staying deliberate and focused is key to making real impactOne-year patent timelines vs. four years – Josh uses USPTO's Track 1 program to secure patents in record time, improving fundraising and M&A positioningClient-centered approach wins – Listening to unique client needs instead of one-size-fits-all strategies earned the firm its #1 rankingDiagnostic patents are back – New USPTO Director signals the patent office is "open for business" again after a decade of restrictionsScientist turned patent attorney – Josh's lab background gives him insider understanding of how innovation actually happensAbout our Guest: Joshua is the patent attorney innovation-driven pharmaceutical companies call when they need to turn complicated technologies into protected assets in record time.As co-managing partner at Nath, Goldberg & Meyer—the #1 ranked patent law firm for biotech and pharmaceutical technologies in both 2024 and 2025—Joshua leads IP efforts across industries like biotech, pharma, agriculture, renewable energy, and advanced materials. Whether it's a blockbuster acne treatment like DUAC, a vitamin D analog lotion like Sorilux, OTC solutions like Salonpas and Germagic, or a leading drug used to reduce stomach acid and treat conditions like GERD, ulcers, and heartburn—like Protonix—Joshua helps turn high-stakes R&D into patent-protected portfolios, often in under a year instead of the typical four-year timeline.Though his climate and agricultre IP expertise has made him famous as the “green patent guy,” Joshua moves between disciplines skillfully and has helped industry leaders like Amgen, Takeda, Guilford Pharmaceuticals, Mayne, and Stiefel Laboratories (which was acquired by GlaxoSmithKline) build pharma portfolios that hold up under investor, acquirer, and FDA scrutiny.His journey didn't begin in IP law, but in the lab, researching experimental pharmaceutical delivery systems. It gave him an edge most attorneys don't have: understanding how innovation actually happens, and how to protect it without slowing a business down. Links Supporting This Episode: Nath, Goldberg & Meyer Website: CLICK HEREJoshua Goldberg LinkedIn page: CLICK HERENath, Goldberg & Meyer LinkedIn: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page:...

Idaho's New Non-Resident Tag Draw Explained – Tara Reichert, IDFG License Operations ManagerIn this episode, we break down Idaho's major overhaul of its non-resident hunting tag system. Chad has special guest, Tara Reichert, Idaho Department of Fish and Game, License Operations Manager on to discuss the new system and how it impacts non-residents.  For 2025, Idaho has moved away from the chaotic first-come, first-served OTC scramble and shifted to a randomized draw designed to level the playing field for everyone.We walk through how the new system works: a 10-day application window in December, the ability to list up to five hunt choices per species, and the option to apply as a group. There's no application fee, but hunters do have to buy a license up front — a change that's already sparked a lot of conversation.Tag results will be released in January, and successful applicants must pick up their tags by the deadline before any leftovers go into a second drawing. Idaho plans to use the data from this new process to better understand demand and guide future wildlife management decisions.If you're planning to chase elk or deer in Idaho, this episode breaks down everything you need to know about navigating the new system.The Important DatesPurchase your 2026 license after December 1 but prior to entering the drawDraw opens December 5Draw closes December 15 (11:59pm MST)Results in early JanuaryTags must be purchased by January 20See the brochure below for additional informationTARA REICHERT, IDFG Website - https://idfg.idaho.govNonresident General Tag Brochure - https://idfg.idaho.gov/sites/default/files/seasons-rules-big-game-supplemental-proclamation-2026-2.pdfGo Outdoors Idaho - https://license.gooutdoorsidaho.com/Licensing/CustomerLookup.aspxInstagram - https://www.instagram.com/idahofishandgame/  OUT OF STATE HUNTER@outofstatehunter  GOHUNTUse the code OUTOFSTATE when you become an Insider and get $50 in GOHUNT Gear Shop Credithttps://www.gohunt.com ARROWHEAD RIFLES - Website -https://arrowheadrifles.comInstagram -https://www.instagram.com/arrowheadrifles/ TRICER USA Use the code OUTOFSTATE and save 10%Website –https://tricerusa.com/Instagram -@tricerusaFacebook -https://www.facebook.com/tricerusa/ DEFIANCE MACHINESave 10% off at Defiance Machine with the code OUTOFSTATE10Website -https://defiancemachine.comInstagram -https://www.instagram.com/defiancemachine/ #outofstatehunter #idaho #idahohunting #westernhunting #biggamehunting #elkseason #elkdeerhunt #overthecountertags #huntingtags #tagstrategy #diyhunter #publiclandhunting #huntwest #huntidaho #nonresidenthunter #backcountryhunting #huntingpodcast #huntmore #gohunt

Did you happen to notice that Tylenol recently launched a dietary supplement product range designed to promote joint comfort and mobility? When the best-selling pain relief brand in the U.S. market launches a drug-free product range…it not only speaks volumes about shifting consumer attitudes from treatment to prevention, but also about the increasing importance of supplements for the pharmaceutical industry. And maybe unsurprisingly to my fellow industry nerds, but this new product launch further strengthens the pharma-nutra convergence trend. In fact, pharmaceutical companies have been increasingly tapping into the preventive segment…seeking new revenue opportunities to mitigate against numerous factors hampering industry profits. Therefore, even during periods of relatively strong demand for OTC drugs, supplements still present an important opportunity to expand the product offering…thus we expect this trend to continue and likely permanently reshape the nutraceutical industry.

FLARE Shocked the XRP Community - Exchanges, Smart Accounts & Real DeFi

Bitcoin Maxi Meltdown – XRP's Big Move With Institutions Bitcoin maxis are melting down this week — and Ripple just handed them another reason to panic. Today we're breaking down: *Ripple Swell 2025 → institutional payments, secure custody, regulated stablecoins *Why XRP's roadmap now lines up perfectly with real-world financial rails *David Schwartz vaporizing Bitcoin Maxis in front of the entire crypto community *Saylor clips creating shockwaves *Plus a breakdown of major geopolitical flashpoints that could drive a global liquidity shift *Where this all leads for XRP, BTC, and the future of institutional crypto This is one of the most important pivot moments for crypto in years. Strap in — this one's going to get spicy.

Send us a textWe dig into how Bluemoth reimagines the path to better hearing by pairing prescription hearing aids with a modern, direct-to-consumer experience that respects privacy, reduces stigma, and preserves clinical outcomes. Born from years of brick-and-mortar practice and leadership in statewide audiology, the model answers a pivotal question: how do we lower the barrier to entry without lowering the standard of care?We trace the spark back to 2017 as OTC legislation moved through Washington State and revealed a split within the profession. Rather than frame OTC as a threat, we explore how access can be an on-ramp, especially when so few people with hearing loss seek help. The inspiration also comes from the eyewear world—think Gentle Monster and Warby Parker—where devices double as identity and the buying journey feels inviting. The goal: bring that sense of agency to hearing technology while keeping expert fitting, counseling, and verification at the core.Step by step, we map the Bluemoth customer journey: a private virtual consultation that reduces intimidation, clear education that demystifies choices, a guided home trial for real-life testing, and a purchase pathway anchored in prescription devices and professional support. Along the way we tackle the real barrier—stigma—not just price, and show how hybrid delivery can duplicate clinical excellence at scale. If you've wondered how to combine boutique-level care with e-commerce convenience, or how to meet patients where they are without compromising outcomes, this conversation offers a pragmatic blueprint.If this resonated, follow the show, share it with a colleague or friend who's been curious about hearing health, and leave a quick review so others can find it. Your feedback helps more people take the first step toward better hearing.Connect with the Hearing Matters Podcast TeamEmail: hearingmatterspodcast@gmail.com Instagram: @hearing_matters_podcast Facebook: Hearing Matters Podcast

XRP ETF Launch, Evernorth's Warning & Trump's Geopolitical Domino XRP is on the edge of a historic moment. Canary Funds just filed its Form 8-A, setting the stage for the first XRP spot ETF to launch as early as tomorrow once Nasdaq certifies the listing. Meanwhile, Ripple hosted the UK Economic Secretary to the Treasury in Singapore to discuss global digital asset competitiveness. Evernorth warns that the financial world is on the brink of a complete reformation and revolution. Coinbase is leaving Delaware and reincorporating in Texas. The U.S. Treasury & IRS just opened staking rewards for crypto ETPs. Senate Ag Committee is pushing new market structure legislation. XRPL developers are shifting views on smart contracts. And geopolitics? Melting down: • Trump's Chinese student proposal sparks national debate over university economics. • Wealthy UK entrepreneurs are fleeing Labour's new exit tax. • JFK's grandson running for Congress while attacking RFK Jr. • A judge orders 615 illegal migrants released after an ICE operation. • More political chaos around Epstein files and media manipulation. This is crypto + geopolitics colliding in real time — and XRP is positioned at the center. Tonight we break it all down with clarity, receipts, and real analysis — no hype. Subscribe, drop a comment, and join the OTC community. ☕ GRAB A BADASSERY COFFEE – Fuel your crypto grind!

Dr. Mindy talks about her trip to the Sphere in Las Vegas. And then she answers questions about bad reactions to alcohol, cuts that wont stop bleeding, GLP ones, eye discharge, Heather had some bloodwork done, discomfort on your right side, small fevers, women with peach fuzz, cramping while pregnant, seasonal allergies in kiddos, tingle fingers, OTC meds for memory improvement, Narrow Ass Nick, eye ptosis, vasectomy reversal, hot ear, bone spurs in da hip and sleeping problems with a anti-depressant. https://www.youtube.com/@TheDrMindyExperiment/videosSee omnystudio.com/listener for privacy information.

Send us a textStigma keeps more people from hearing help than price does, and we're tackling that head on with a model that puts privacy, speed, and clinical integrity at the center. Blaise sits down with Dr. Melanie Hecker, founder of BLUEMOTH and owner of five brick‑and‑mortar clinics, to unpack a digital prescription approach that feels modern without sacrificing professional care. Think premium devices you can test at home, real clinicians guiding each step, and service that moves at the speed of life.We dig into the full customer journey: a private online consult, candidacy confirmed through a recent audiogram or a shipped test kit that includes air, bone, speech, and speech‑in‑noise, plus clear referrals when red flags pop up. The standout moment is the Experience Box—three sets of top‑tier hearing aids, first‑fit to about 85–90 percent, so users can compare sound quality, comfort, and features in the real world. An audiology assistant handles unboxing and setup, and follow‑ups in the first weeks keep progress on track. When issues require deeper adjustments, BLUEMOTH ships a laptop and Noahlink Wireless to unlock full software‑level tuning and feedback testing from home.We also confront the big question: validation. Dr. Hecker explains why she won't “check the box” on remote real-ear measurements (REMs) until it can be done with accuracy and integrity, and she lays out a realistic path forward—referrals for REM today, and future 3D ear scans to model real‑ear targets without probes. Add rapid response times, overnight loaners for device failures, strong connectivity, and pricing that sits between OTC and boutique clinics, and you get a hybrid that serves GenX, younger boomers, busy professionals, and families supporting older adults with mobility challenges.If you care about access, outcomes, and the future of hearing healthcare, this conversation is a blueprint. Subscribe, share with a friend who's been putting off a hearing check, and leave a review telling us which part of the hybrid model you'd adopt first. Connect with the Hearing Matters Podcast TeamEmail: hearingmatterspodcast@gmail.com Instagram: @hearing_matters_podcast Facebook: Hearing Matters Podcast

Cavities are still one of America's most common diseases – despite decades of fluoride use. Xlear is calling on the FDA to recognize xylitol as an active anticaries ingredient so dental professionals and patients can finally access this powerful tool. Xylitol, a safe and natural compound, has been proven to stop cavity- causing bacteria and dramatically reduce tooth decay.The American Dental Hygienist Association (ADHA) in conjunction with Xlear, a leader in hygiene products, filed a citizen petition with the U.S. Food & Drug Administration (FDA) urging the FDA to formally recognize xylitol as an approved Over-the-Counter (OTC) active ingredient in dental hygiene products, including toothpaste, rinses, gels, mouthwashes, gums, and lozenges.Xylitol addresses the root cause of tooth decay. In contrast, fluoride strengthens tooth enamel. Fluoride has almost no effect on the bacteria that causes tooth decay. Studies have shown that xylitol has a higher “protection factor” in fighting cavities than fluoride.“Dental decay is the single most common communicable, chronic disease inflicting Americans today. Moreover, dental decay is also closely associated with driving other serious health risks - ranging from heart disease to diabetes,” said Trisha O'Hehir, MS, RDH.Key Facts:·         Nearly 90% of U.S. adults have experienced tooth decay.·         Studies show xylitol can reduce cavities by up to 80%.·         Xylitol works by neutralizing acid-producing bacteria and protecting enamel at the source.·         Xylitol is safe if swallowed, a key benefit for children.·         Widely used internationally, xylitol is already found in gum and oral hygiene products. The petition requests that FDA: Amend 21 C.F.R. Part 355 to list xylitol as an approved anti-caries active ingredient. Alternatively, issue a new OTC monograph under Section 505G of the FDCA.Learn more about the Petition hereXlear is one of the nation's leaders in effective xylitol hygiene products, available inpharmacies, big box stores, natural retailers and online.XLEAR's Retailers: Walgreens, CVS, Vitamin Shoppe, Target, Kroger, Sprouts, Natural Grocers and most natural products retailers nationwide.XLEAR's Online Retailers: Amazon, iHerb, Lucky Vitamin, and Vitacost.comLearn more at Xlear.com or SprySmile.com 

XRP Builder Burnout — Has Crypto Already Lost to Stablecoins? Has crypto already lost to stablecoins? The XRP community is feeling the strain — experiencing burnout, stalled growth, and a decline in innovation. Tonight we ask the hard question: Without XRP builders, is there even a future for crypto as stablecoins take over? We'll break down:

XRP - Ripple Swell 2025 Recap | NYC is now socialist? | Geopolitics

Ripple Explodes to $40 Billion Valuation — What It Means for XRP & Crypto! Big move in the crypto world: Ripple has secured $500 million in fresh capital, pushing its valuation to around $40 billion. In this video we unpack: *Who backed the round (including Fortress Investment, Citadel Securities, and more) *How this fits into Ripple's strategy (stablecoins, institutional custody, payments) *The implications for XRP holders and token markets *What it signals about crypto-industry maturation and institutional adoption If you're following XRP, Ripple's evolution or looking for the next big shift in crypto powerhouses—this is one you don't want to miss.

Dr. Michael Hall, a family medicine physician at UK HealthCare — Georgetown, shares valuable knowledge about over-the-counter (OTC) medications that are commonly used during the cold and flu seasons. Dr. Hall talks about ingredients, when to take medications and how to know when you should see your primary-care physician or an urgent-care provider.

What if you could know—before you ever give a pill—whether your dog or cat is likely to have a bad reaction? In this episode, Dr. Alice and Janet sit down with Dr. Katrina Mealey, Associate Dean for Research at Washington State University's College of Veterinary Medicine, NIH-funded researcher, and Inventor of the Year for her groundbreaking genetic test that flags pets at risk for serious adverse drug reactions.Dr. Mealey explains the science in plain English: a natural “gatekeeper” protein called P-glycoprotein (coded by the MDR1 gene) protects the brain and body by pumping out potentially toxic compounds. When a pet carries certain MDR1 mutations, many common medications—prescription and OTC—can reach dangerous levels. We cover how the cheek-swab test works, how to get it for your pet, which breeds are most affected, why dosage matters so much, and how new vet-friendly tools help tailor safer treatments.In this episode:- MDR1 101: What P-glycoprotein does and why it's the body's drug “gatekeeper.”- Who's at risk: Collies (~75%), Australian & English Shepherds (~50%), plus surprises like Boxers, Huskies, and even the occasional Golden—plus the feline version discovered in 2015.- Real-world reactions: From anti-diarrheals and chemo agents to certain flea preventives—how problems present and what vets should watch for.- Testing made easy: Simple cheek swab or blood test; results emailed to you and your vet.- Dosing guidance: Meet MDR1Caddie (dogs) and WhisPurr (cats)—information that suggests dose adjustments based on whether a pet has one or two copies of the mutation.- Myth-busting ivermectin: Why tiny monthly heartworm doses are different from mange/cancer “DIY” dosing—and why self-medicating is dangerous.- Take-home for pet parents: Bring MDR1 status up with your vet before surgeries, chemo, dermatology meds, new preventives, or simple OTC medications like Immodium.About our guestDr. Katrina Mealey is a veterinarian, pharmacist, researcher, and author (editor of Pharmacotherapeutics for Veterinary Dispensing). Her lab identified the MDR1 mutation in dogs and later in cats, and continues to map which drugs interact with P-glycoprotein so veterinarians can treat more safely.https://vetmed.wsu.edu/our-team/wsu-profile/kmealey/Resources & links- MDR1 genetic test: Link in show notes to order a cheek-swab kit for dogs or cats.- Drug interaction updates: Ongoing lists and guidance are available via the testing program (see show notes).- Dose-adjustment information: MDR1Caddie (dogs) and WhisPurr(cats).- Talk to your veterinarian before starting, stopping, or changing any medication.--What started during the COVID-19 lockdown with one baby gorilla at the Cleveland Zoo has grown into a channel loved by animal fans around the world. I'm a one-person operation—filming, editing, narrating, and sharing the most heartfelt moments of baby gorillas, orangutans, elephants, and other zoo animals. Whether it's Jameela's emotional journey or Clementine's first steps, each video brings you closer to the animals and their stories. If you love watching real animal behavior, learning fun facts, and supporting conservation through storytelling—this is your place! Subscribe to Larry's Animal Safari on YouTube @larrysanimalsafari ---Support our sponsor for this episode Blue Buffalo by visiting bluebuffalo.com. BLUE Natural Veterinary Diet formulas offer the natural alternative in nutritional therapy. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents.---All footage is owned by SLA Video Productions.

Send us a textIn this episode of the WTR Small-Cap Spotlight Podcast, Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group, joins hosts Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, and Shawn Severson, WTR Co-Founder and CEO. The discussion explores OTC's expanding global footprint, the surge in cross-border trading activity, and the company's role in connecting international issuers with U.S. investors. Paltrowitz highlights rising European and Canadian engagement, the “list local, trade global” model, and new opportunities ahead in Asia and overnight trading as OTC continues to enhance global market efficiency heading into 2026.

Vadim Rozov, CEO at Simplify Labs (⁠https://simplifylabs.io/en/) Simplify Labs specializes in developing crypto platforms that comply with European regulatory frameworks. Founded by the creators of Kyrrex, a MiCA-compliant cryptocurrency exchange, the company provides solutions that meet EU regulatory standards. It also offers legal, marketing, and customer support services to crypto projects. Its core expertise includes building crypto exchanges, OTC platforms, crypto Telegram bots, and liquidity hubs.

Vadim Rozov, CEO at Simplify Labs (⁠https://simplifylabs.io/en/⁠). Simplify Labs specializes in developing crypto platforms that comply with European regulatory frameworks. Founded by the creators of Kyrrex, a MiCA-compliant cryptocurrency exchange, the company provides solutions that meet EU regulatory standards. It also offers legal, marketing, and customer support services to crypto projects. Its core expertise includes building crypto exchanges, OTC platforms, crypto Telegram bots, and liquidity hubs.

$1B Into XRP?! Evernorth Just Changed Everything Evernorth — backed by Ripple — is making headlines with a $1 billion XRP treasury move, and it's sending shockwaves through the entire crypto world. In today's show, Jeff & Chip break down: • How Evernorth's massive XRP allocation could redefine institutional adoption. • What Digital Asset Treasuries (DATs) mean for traditional finance. • Insights from Asheesh Birla, Joel Katz (David Schwartz), and Michael Arrington live from Swell 2025. • The bigger picture — is this the start of a full-scale TradFi-to-DeFi shift?

Hoy conversamos con Eva Prados, ex candidata al Distrito 3 de San Juan y actual Coordinadora General del Movimiento Victoria Ciudadana (MVC). Hablamos sobre su trayectoria política, las lecciones que ha aprendido tras dos campañas, su relación con el activismo, y cómo navega las tensiones entre la calle y la política partidista. También discutimos el estado actual del MVC, las críticas sobre su identidad ideológica y carisma, y el futuro de las alianzas con el PIP y otros movimientos. ¿Sigue creyendo en el proyecto original del MVC? ¿Cómo ve el panorama hacia 2028?Y, claro, respondimos varias de las preguntas enviadas por la comunidad del Patreon. Si fueras integrante de nuestro Patreon, hubieras escuchado este episodio ayer. Únete ahora en patreon.com/puestospalproblema! Presentado por

XRP Rises | Elizabeth Warren Rages Against Crypto | Trump & Global Power Shift The XRP Ledger is on fire — tokenized real-world assets up 215%, XRP price up 27%, and institutional adoption is accelerating. But in Washington, panic sets in. Elizabeth Warren, Adam Schiff, and the anti-crypto bloc are pushing new legislation after Trump pardons former Binance CEO CZ — while Trump's global influence grows from South Korea to the G20 stage. Join Jeff and Chip on On The Chain as they connect the dots between: XRP's institutional surge Ripple's RWA expansion The war on crypto inside DC Trump's global comeback Elon Musk warning of UK unrest and what this all means for the next financial era ☕ Grab your Badassery Coffee: badasserycoffee.com

Most people assume that if a drug sits on the shelf at Costco or Walgreens, it must be pretty safe. But what if some of the most common over-the-counter (OTC) medications are among the riskiest drugs in America? On this episode of Vitality Radio, Jared exposes the hidden dangers behind everyday pain relievers, sleep aids, and heartburn drugs—medicines that cause thousands of deaths every year when misused or taken long-term. You'll learn how a drug becomes “OTC,” what happens when pharmaceutical companies push for that switch, and why the FDA's approval process might not tell the whole story. Jared dives into the startling realities of PPIs like Prilosec, NSAIDs like ibuprofen, and acetaminophen (Tylenol)—uncovering their risks to the liver, kidneys, bones, and brain. He also discusses how marketing convinces consumers these drugs are harmless. Finally, Jared offers a resource for safe, natural alternatives for reflux, pain, inflammation, sleep, and immune support—options that nourish the body instead of depleting it. This episode will change the way you look at “harmless” OTC drugs and help you take real control of your health.Just Ingredients Lemon Swish Protein Powder Vitality Radio POW! Product of the Week $29.99 per bag (regular price $59.99) with PROMO CODE: POW15Additional Information:#341: Your Digestive Health Supplement User's Guide. From IBS to Acid Reflux - Learn How to Balance Your Gut Health With Natural Products. #522: Q&A Show #5 - Jared Answers Your Questions About Energy and Sleep!#471: Boosting Your Immune System Ahead of Winter #553: Boswellia & Curcumin: Nature's Dream Team for Pain & Inflammation with Dr. Lexi LochVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

NSAIDs are everywhere, prescription, OTC, topical, oral, injectable, you name it! In an era of Opioidphobia, are they really a panacea? Heck no, all medications come with baggage. We could spend hours talking about NSAIDs, and not even get to the elephant in the room: Which NSAID for Which Patient? So we'll go there in this succinct, yet comprehensive rapid review of all things NSAIDs on the Pain Pod! Come one, come all, to the Pain Pod!!! Pain Guy • www.painguy.us

Trump's CFTC Pick Changes Everything | XRP: The Fix Is In

Ripple Prime Is Live! XRP is Everything | CZ Pardoned by Trump Ripple just went full Wall Street. Hidden Road → Ripple Prime is official — making Ripple the first crypto company to own and operate a global, multi-asset prime broker. Brad Garlinghouse says XRP is at the center of everything Ripple builds — and this move proves it. At the same time, CZ is officially pardoned by President Trump, shocking the establishment and reigniting the crypto freedom narrative. Plus: the White House ballroom controversy, digital ID expansion in the UK, and how all of this ties into global control and financial sovereignty. *** SUPPORT ON THE CHAIN GRAB A BADASS YETIS COFFEE – Fuel your crypto grind! ☕ Visit: otc.one/BadassYetisBrew MINT YOUR BADASS YETIS NFT – Own a piece of the legend! Visit: otc.one/mint OTC MERCH IS HERE! – Represent the community in style! Visit: onthechain.shop BUY US A COFFEE – Help keep the content flowing! Visit: otc.one/buy-us-a-coffee JOIN THE CHANNEL – Get exclusive perks & behind-the-scenes content! Visit: otc.one/join ********** ON THE CHAIN – CONNECT WITH US! Listen to the OTC Podcast – Never miss an update! Visit: otc.one/podcast Visit Our Website – The home of crypto insights! Visit: onthechain.io Follow OTC on Twitter – Stay updated in real time! Visit: otc.one/otc Join the OTC Community on Twitter – Be part of the discussion! Visit: twitter.com/i/communities/1599435678995062788 ********** FOLLOW THE OTC TEAM Follow Jeff on Twitter:

Over-the-counter (OTC) pain and fever medications are widely used despite having marginal efficacy and significant side effects that hospitalize hundreds of thousands of Americans each year While a widespread practice, using these medications to reduce fevers has long been controversial, both due to their toxicity and the notion that fevers are essential for health During the 1918 Influenza pandemic, one of the most critical lessons was that avoiding fever suppression was vital for protecting patients from dying While considered the “safest” option, Tylenol has a wide range of issues, including liver damage, gastrointestinal issues, blood cancers, and kidney injuries An extensive body of data connects using Tylenol during pregnancy or in infancy to the development of neurological injuries (e.g., autism). Many of these tragic cases illustrate a longstanding observation within natural medicine — suppressing superficial reactions (e.g., fevers) can transform illnesses into chronic ailments that can cause far more issues

My interview with Taran Sabharwal, Founder and CEO of Stix.  - How private OTC #crypto markets are handling over $1B in monthly volume  - The cyclical nature of secondaries and locked token trading  - Who's selling: VC funds and foundations  - Who's buying: prop trading firms, family offices, and private wealth  - Case study: #Solana secondaries moving from 50% to 15% discount  - How digital asset treasury firms are enabling access for traditional capital  - The arbitrage opportunity between discounted tokens and liquid futures  - Why #ETFs can't compete with token treasuries on flexibility and yield  - The growing role of market-neutral strategies in altcoin investments  - Long-term outlook on institutional access to crypto via equity structures Powered by Phoenix Group Powered by Phoenix Group The full interview is also available on my YouTube channel: YouTube: http://bit.ly/42Ue7gK    

Note: I had some mic issues so this was recorded on Mac speakers. May need to turn it up a bit Question topics:Block vs. concurrent periodization (SOF prep)Optimizing early AM PT testsHigh vs. low rep squats for SFAS prepWhy I left the militaryHow hard is CQB in OTC?Pre race/test/event self-talkLast 6 months pre-OSUT (18X)PT tests fatigued vs. freshBody comp vs. performance pre dive schoolEffects of 1 month off trainingHigh step count pre-SFASConditioning & hypertrophyCrosstraining for run gainsLog PT at SFAS?Fat but also fast (How?)---Questions? Look for bi-weekly Q&A on my stories. I'll answer your questions on IG and here on the podcast.---Spoken Supplements: Code terminator_trainingCwench supplements: Code terminator_training---New Selection Prep Program: Ruck | Run | Lift Ebook: SOF Selection Recovery & Nutrition Guide---TrainHeroic Team Subscription: T-850 Rebuilt (try a week for free!)---PDF programs2 & 5 Mile Run Program - run improvement program w/ strength workKickstart- beginner/garage gym friendlyTime Crunch- Workouts for those short on timeHypertrophy- intermediate/advancedJacked Gazelle- Hybrid athleteJacked Gazelle 2.0 - Hybrid athleteSFAS Prep- Special forces train-upRuck | Run | Lift - Selection Prep---Let's connect:Newsletter Sign UpIG: terminator_trainingYoutube: Terminator Training Methodwebsite: terminatortraining.comSubstack

Regulatory changes and shifting market dynamics are shining a spotlight on repo clearing. Amid all the changes, Yama Darriet, Head of OTC and Repo Expansion at Euronext, stops by the show to discuss the factors that are driving more firms to turn to repo clearing. Darriet also outlines Euronext's Repo Expansion Initiative, which aims to boost market access, liquidity provision and collateral optimization across Europe. Darriet also provides an update on Euronext's effort to bring the buy side into clearing via the build out of its Sponsored Access solution.Sign up for Modern Money SmartBrief

The CPG Guys are joined in this episode by Zach Dennett, VP Merchandising for Consumer Health and Wellness, and Supplemental Benefits at CVS Pharmacy, the Front-Of-Store Retail Business Unit of CVS Health. Follow Zach on LinkedIn at: https://www.linkedin.com/in/zacharydennett/ Follow CVS Health online at: http://cvshealth.comFollow CVS Health on LinkedIn at: https://www.linkedin.com/company/cvshealth/Zach answers these questions:Since stepping into your current role in March 2024, what has been your primary focus within Consumer Health & Wellness front of store merchandising at CVS Health?CVS emphasizes seamless omnichannel experiences. What are key milestones in merging in-store and digital merchandising? With around 60 million digitally engaged customers, what are the biggest learnings about how digital influences in-store purchases in your category?What qualities do you look for in emerging brands seeking merchandising partnerships with CVS Health?CVS stores have shoppers coming for Rx, for OTC and even primary healthcare needs. How do you work with the other business owners within CVS Health to ensure your shoppers get the care that they need and how do brands play a role in this process?Could you share how your merchandisers interact with CVS Media Exchange to ensure that brands connect with your consumers in the path to purchase?What role does behavioral insights via loyalty data (e.g., ExtraCare insights) play in determining your merchandising strategies? In other statements, you've noted younger generations trust influencers over experts. How does this affect product merchandising strategy? How do you see CVS's merchandising role evolving over the next 3–5 years amid innovations like “instant commerce”?CPG Guys Website: http://CPGguys.comFMCG Guys Website: http://FMCGguys.comRhea Raj's Website: http://rhearaj.comLara Raj in Katseye: https://www.katseye.world/DISCLAIMER: The content in this podcast episode is provided for general informational purposes only. By listening to our episode, you understand that no information contained in this episode should be construed as advice from CPGGUYS, LLC or the individual author, hosts, or guests, nor is it intended to be a substitute for research on any subject matter. Reference to any specific product or entity does not constitute an endorsement or recommendation by CPGGUYS, LLC. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. CPGGUYS LLC expressly disclaims any and all liability or responsibility for any direct, indirect, incidental, special, consequential or other damages arising out of any individual's use of, reference to, or inability to use this podcast or the information we presented in this podcast.